EVOLUS, INC. Gain (Loss) Related to Litigation Settlement
EVOLUS, INC. (EOLS) reported Gain (Loss) Related to Litigation Settlement of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-08.
Discontinued › Income Statement › Other Income
us-gaap:GainLossRelatedToLitigationSettlement · last filed 2023-03-08
- EVOLUS, INC. gain (loss) related to litigation settlement for the quarter ending 2022-12-31 was $0.00.
- EVOLUS, INC. gain (loss) related to litigation settlement for the quarter ending 2022-09-30 was $0.00.
- EVOLUS, INC. gain (loss) related to litigation settlement for the quarter ending 2022-06-30 was $0.00.
- EVOLUS, INC. gain (loss) related to litigation settlement for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- EVOLUS, INC. gain (loss) related to litigation settlement for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- EVOLUS, INC. gain (loss) related to litigation settlement for fiscal 2021 was $25.50M.
| Period end | Gain (Loss) Related to Litigation Settlement 1 month | Gain (Loss) Related to Litigation Settlement 3 month | Gain (Loss) Related to Litigation Settlement 6 month | Gain (Loss) Related to Litigation Settlement 9 month | Gain (Loss) Related to Litigation Settlement 12 month |
|---|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $0.00 derived: sum of 2 quarters · filed 2023-03-08 | $0.00 derived: sum of 3 quarters · filed 2023-03-08 | $0.00 10-K · filed 2023-03-08 | |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | $0.00 derived: sum of 4 quarters · filed 2023-03-08 | |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-02 | $0.00 10-Q · filed 2022-08-02 | $0.00 derived: sum of 3 quarters · filed 2023-03-08 | $0.00 derived: sum of 4 quarters · filed 2023-03-08 | |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-10 | $0.00 derived: sum of 2 quarters · filed 2023-03-08 | $0.00 derived: sum of 3 quarters · filed 2023-03-08 | $0.00 derived: sum of 4 quarters · filed 2023-03-08 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $0.00 derived: sum of 2 quarters · filed 2023-03-08 | $0.00 derived: sum of 3 quarters · filed 2023-03-08 | $25.50M 10-K · filed 2023-03-08 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $25.50M 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-02 | $25.50M 10-Q · filed 2022-08-02 | |||
| 2021-04-30 | $25.50M 10-K · filed 2022-03-03 | ||||
| 2021-03-31 | $25.50M 10-K · filed 2023-03-08 | $25.50M 10-Q · filed 2022-05-10 | |||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-02 | $0.00 derived: sum of 2 quarters · filed 2021-11-02 | $0.00 10-Q · filed 2021-11-02 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-04 | $0.00 10-Q · filed 2021-08-04 | |||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |